Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00080340 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

520

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Carcinoma

Interventions

DRUG: TLK286 (Telcyta) HCl for Injection
DRUG: gefitinib (Iressa)

Sponsor

Telik